Abstract
In the last decade, explosion in therapeutic op-tions for management of type 2 diabetes mellitus (DM) have increased significantly with advances in recombinant DNA technology, molecular bi-ology, clinical chemistry; analogs of insulin have replaced animal insulin, and may displace NPH, regular lente, ultra lente, insulin’s. Analogs such as insulin glargine, insulin lispro, insulin aspart, and insulin glulisine are becoming mainstream therapy for even type 2 DM Besides oral hypo-glycemic agents i.e., sulphonyl ureas, biguanides and thiazolidinediones, newer insulin analogs and non-insulin antidiabetics are in various stages of development. Incretin analogs, amylin analogs, combined P PAR-γ and α agonists, islet-neogenesis gene-associated protein (INGAP) are most prominent amongst these. This review fo-cuses on pramlintide, an amylin analog, GLP-1 agonists and exenatide, an exendin 4 analog re-cently approved for use in type 2 diabetes by US FDA. Newer insulin delivery methods and drugs have also been reviewed.
Keywords
Fulltext
This part is available in the PDF file.
References
-
1.
The references are available in the PDF file.
Copyright
© 2006, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.